Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810–1834. doi: 10.1016/j.jacc.2023.01.049
2.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476–2486. doi: 10.1016/j.jacc.2017.08.074
3.
Desai AS, Vaduganathan M, Cleland JG, Claggett BL, Barkoudah E, Finn P, McCausland FR, Yilmaz MB, Lefkowitz M, Shi V, et al. Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF trial. Circ Heart Fail. 2021;14:e008597. doi: 10.1161/CIRCHEARTFAILURE.121.008597
4.
Jha AK, Ojha CP, Krishnan AM, Paul TK. Thirty-day readmission in patients with heart failure with preserved ejection fraction: insights from the nationwide readmission database. World J Cardiol. 2022;14:473–482. doi: 10.4330/wjc.v14.i9.473
5.
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, et al; American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148:1606–1635. doi: 10.1161/CIR.0000000000001184
6.
Yang M, Dewan P, Desai AS, Lam CSP, Lefkowitz MP, Packer M, Rouleau JL, Vaduganathan M, Zile MR, et al. Impact of multimorbidity on mortality in heart failure with mildly reduced and preserved ejection fraction. Circ Heart Fail. 2025;18:255–268. doi: 10.1161/CIRCHEARTFAILURE.124.011598
7.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, et al; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620. doi: 10.1056/NEJMoa1908655
8.
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34–42. doi: 10.1161/CIRCULATIONAHA.114.013255
9.
Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475. doi: 10.1056/NEJMoa2407107
10.
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757–767. doi: 10.1016/S0140-6736(22)01429-5
11.
Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–1084. doi: 10.1056/NEJMoa2306963
12.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–2232. doi: 10.1056/NEJMoa2307563
13.
Fudim M, Borlaug BA, Mohan RC, Price MJ, Fail P, Goyal P, Hummel SL, Zirakashvili T, Shaburishvili T, Patel RB, et al. Endovascular ablation of the greater Splanchnic nerve in heart failure with preserved ejection fraction: the REBALANCE-HF randomized clinical trial. JAMA Cardiol. 2024;9:1143. doi: 10.1001/jamacardio.2024.2612
14.
Stone GW, Lindenfeld J, Rodes-Cabau J, Anker SD, Zile MR, Kar S, Holcomb R, Pfeiffer MP, Bayes-Genis A, Bax JJ, et al. Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial. Circulation. 2024;150:1931. doi: 10.1161/CIRCULATIONAHA.124.070870
15.
Chunawala ZS, Qamar A, Arora S, Pandey A, Fudim M, Vaduganathan M, Bhatt DL, Mentz RJ, Caughey MC. Prevalence and prognostic significance of polyvascular disease in patients hospitalized with acute decompensated heart failure: the ARIC study. J Card Fail. 2022;28:1267–1277. doi: 10.1016/j.cardfail.2022.01.002
Information & Authors
Information
Published In
Copyright
© 2025 American Heart Association, Inc.
Versions
You are viewing the most recent version of this article.
History
Published in print: March 2025
Published online: 3 March 2025
Keywords
Subjects
Authors
Disclosures
None.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.